Each group consisted of equal distributed tumor volumes and similar mean volumes ± standard deviation at start of treatment with 132 + 56 mm3, 134 + 44 mm3, 128 + 45 mm3, 131 + 55 mm3, 137 + 42 mm3, 127 + 33 mm3 for 5-FU/Irino, anti-VEGF, anti-VEGF+5-FU/Irino, CrossMab, CrossMab+5-FU/Irino, PBS control, respectively. The gene discussed is VEGFA; the disease is neoplasm.